# Hepion Pharmaceuticals, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Hepion Pharmaceuticals, Inc.). ## Overview Hepion Pharmaceuticals, Inc. is a U.S.-based biopharmaceutical company that has historically focused on developing drug candidates and, more recently, has expanded into in-licensed diagnostic tests. The company has no approved commercial pharmaceutical products and is still in a development-stage, capital-dependent profile, with operations funded primarily through equity, warrants, and other financing instruments. ## Products & services • Drug development and clinical-stage pharmaceutical programs • In-licensed diagnostic tests for celiac disease and respiratory infections • H. pylori diagnostic test • Hepatocellular carcinoma (HCC) diagnostic test rights • European commercialization of CE-marked diagnostic products - **Clinical-stage pharmaceutical programs** (0%) — Research, preclinical work, and clinical development of drug candidates and related technologies. - **In-licensed diagnostics** (100%) — Diagnostic tests licensed from New Day Diagnostics, including celiac, respiratory multiplex, H. pylori, and HCC tests. - **Regulatory and commercialization rights** (0%) — Rights to sell CE-marked diagnostic products in Europe and pursue regulatory, sales, and reimbursement milestones. - Drug development and clinical-stage pharmaceutical programs - In-licensed diagnostic tests for celiac disease and respiratory infections - H. pylori diagnostic test - Hepatocellular carcinoma (HCC) diagnostic test rights - European commercialization of CE-marked diagnostic products ## Customers Hepion’s historical customer base is not a traditional recurring buyer base because the company has not generated operating revenue from its pharmaceutical programs. Its near-term commercial opportunity is tied to European buyers of CE-marked diagnostic tests, including healthcare providers, laboratories, and distributors, while future pharmaceutical customers would be patients and prescribers if a product is approved. - **European diagnostic buyers** (primary) — Hospitals, labs, and distributors that can purchase CE-marked celiac, respiratory multiplex, and H. pylori tests for immediate sale in Europe. - **Healthcare providers and labs** (primary) — Clinical end users that would adopt the tests based on workflow fit, turnaround time, and disease screening needs. - **Payers and reimbursement bodies** (secondary) — Organizations that affect pricing, reimbursement, and scale-up of diagnostic sales in target markets. - **Future pharmaceutical prescribers and patients** (emerging) — Potential end users of any approved drug candidate from Hepion’s development pipeline. - European healthcare providers that may buy CE-marked diagnostic tests - Clinical laboratories needing celiac, respiratory, or H. pylori testing - Distributors and channel partners for diagnostic commercialization - Patients and physicians, if future drug candidates reach approval - Licensing and reimbursement stakeholders that influence adoption ## Geography Hepion is headquartered in the United States, but its disclosed near-term commercialization opportunity is in Europe because three licensed diagnostic products have CE marks and are eligible for sale there. The company currently has no commercial products approved for sale in the U.S., so geography matters mainly through regulatory access, reimbursement, and the ability to build a European sales channel. - United States is the corporate base and historical R&D center - Europe is the near-term commercial market for CE-marked diagnostics - No approved commercial products in the U.S. today - European revenue depends on regulatory, sales, and reimbursement execution - Geographic expansion is tied to licensing and commercialization milestones ## Strategy Hepion’s strategy has shifted from a pure drug-development model toward strategic alternatives and in-licensed diagnostics that can be commercialized sooner. Management is focused on preserving liquidity, reducing burn, and creating a path to revenue through CE-marked products while still retaining optionality around future development assets. - **Launch and monetize licensed diagnostics in Europe** (short-term) — These products are the only disclosed near-term revenue opportunity and can generate sales before any drug approval. - **Secure additional financing** (short-term) — The company has no operating revenue and must fund ongoing development, licensing, and commercialization activities. - **Reduce operating burn** (short-term) — Lower cash usage extends runway and supports execution while the company transitions its business model. - **Retain strategic optionality** (medium-term) — Management continues to evaluate acquisitions, licensing, and other alternatives to rebuild the pipeline. - Commercialize CE-marked diagnostics in Europe - Pursue regulatory, sales, and reimbursement milestones - Preserve cash through reduced R&D and headcount - Use licensing to shorten time to market - Maintain strategic flexibility for future asset acquisition - Seek additional financing to fund operations ## Risks Hepion remains a high-risk, development-stage company with no approved commercial products and a history of operating losses. Its ability to continue depends on raising capital, successfully commercializing licensed diagnostics, and navigating regulatory and reimbursement hurdles in Europe and beyond. - **Going-concern and liquidity risk** [critical] — The company has no approved products and expects continued losses, so it may need additional capital to operate. - **Regulatory approval and compliance risk** [high] — Commercialization depends on meeting FDA and foreign regulatory requirements, and approvals can be delayed, limited, or withdrawn. - **Commercialization and reimbursement risk** [high] — Even CE-marked products may not generate meaningful revenue if adoption, pricing, or reimbursement is weak. - **Dilution risk from capital raises** [high] — Funding has come from equity, warrants, and preferred stock, which can dilute existing shareholders. - **Development failure risk** [high] — Pharmaceutical candidates can fail in preclinical or clinical testing or prove unsafe or ineffective. - No commercial revenue base and ongoing operating losses - Need for repeated equity or debt financing - Clinical, regulatory, and commercialization execution risk - Dependence on licensed products and third-party rights - Potential dilution from warrants, preferred stock, and offerings - Fair value volatility from derivative instruments and contingent consideration ## Accounting The most important accounting issues are valuation-based rather than revenue-based because the company has no operating revenue and relies on financing instruments. Investors should watch fair value changes in derivatives and contingent consideration, impairment charges, and the accounting for equity-linked financings that can materially affect reported losses and equity. - **Fair value of derivative financial instruments** — Reported net loss can change materially period to period. - **Contingent consideration** — Can increase liabilities and create volatility in other income/expense. - **Asset impairment** — Can reduce asset values and increase operating loss. - **Equity-linked financing accounting** — Important for per-share metrics and capital structure interpretation. - No operating revenue, so results are driven by expenses and financing items - Fair value changes in derivatives can swing net loss materially - Contingent consideration requires judgment and remeasurement - Asset impairment losses may reflect reduced value of acquired or licensed assets - Equity and warrant issuances affect dilution and APIC --- *Last updated: 2026-04-28T20:14:40.635337+00:00*